BMS Archive

Plant · Scientific monograph

Sabdariffa gossypiifolia

Roselle / Hibiscus sabdariffa

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Blood Pressure Mechanisms, Cardiovascular Research

Research overview

Historical use

Roselle calyces, reported in the literature as Hibiscus sabdariffa, are used as sour beverages and in traditional medicine in Africa and Asia; this history is distinct from clinical evidence [2][6].

Modern research context

Roselle calyx infusions have been studied for blood-pressure outcomes, with substantial preparation and study-quality limitations [1][2]. In a double-blind trial of 65 adults aged 30–70 years with prehypertension or mild hypertension who were not taking blood-pressure medicines, a six-week calyx-tea regimen reduced systolic pressure more than placebo; the diastolic difference was not significant [1]. A review of 17 chronic trials found a systolic-pressure signal but very high heterogeneity (I²=95% in the placebo comparison); this supports a conservative Level B for the studied blood-pressure outcomes, not proven cardiovascular-event prevention or medication equivalence [2]. A 25-man acute crossover study improved flow-mediated dilation without a significant blood-pressure reduction [4].

Adverse effects

Mild, transient gastrointestinal symptoms were reported in one trial summarized by the review; short trials and incomplete reporting cannot establish long-term safety or rare-event rates [2]. Hypersensitivity is a regulatory contraindication [6].

Contraindications

Hypersensitivity to roselle or related Malvaceae is listed by EDA [6]. Low blood pressure and concurrent blood-pressure treatment warrant precautionary clinical assessment because additive effects are plausible [2][6]. Medicinal use in children is insufficiently characterized in these sources. EDA includes a precaution to stop two weeks before planned surgery because of possible glucose effects; a clinical perioperative benefit of that interval has not been established [6].

Clinical and phytochemical data

Used part

Fleshy red calyces, usually dried and infused in water; tea and concentrated extracts have different constituent exposures. Clinical sources use the synonym Hibiscus sabdariffa [1][5][6].

Primary active compounds

  • Delphinidin-3-sambubioside (anthocyanin) [2][3]

  • Cyanidin-3-sambubioside (anthocyanin) [2][3]

  • Phenolic acids including gallic acid [4]

  • Hibiscus acid and related organic acids [6]

Mechanism of action

Animal and in-vitro work summarized in the review investigates angiotensin-converting enzyme (ACE), vascular calcium influx and endothelial nitric-oxide signaling; these hypotheses do not establish clinical ACE inhibition or explain all human effects [2]. Human flow-mediated dilation improved in one small acute trial, but nitric-oxide and blood-pressure changes were not significant [4].

Pharmacokinetics

Absorption

In six healthy volunteers given a single Hibiscus extract, measured intact anthocyanins peaked in plasma at a median 1.5 hours. These abstract-level, compound-specific findings cannot describe absorption of the complete botanical or establish calyx-product dosing [3].

Distribution

Human tissue distribution and protein binding of complete calyx extracts were not established in the selected sources [2][3].

Metabolism

A small human crossover trial detected circulating gallic acid and methylated phenolic acids after an aqueous calyx drink; complete metabolic pathways and clinically relevant CYP effects remain unresolved [4].

Excretion

In six volunteers, 0.018% of the administered total anthocyanins was recovered as measured intact anthocyanins in urine within seven hours. This is not total recovery of all metabolites; extract-level clearance and impairment adjustments are unknown [3].

Safety and interactions

Drug interactions

Additive hypotension with antihypertensive drugs is a precautionary pharmacodynamic concern [2][6]. EDA also flags chloroquine, simvastatin and diabetes medicines, but this extraction has not independently verified the underlying clinical interaction studies; direction and magnitude must not be assumed [6]. A hydrochlorothiazide interaction described in the review was in rats and is not an established human interaction [2].

Toxicity

No reliable long-term human toxicity threshold is established. Short trial tolerability and animal toxicity results do not establish safety during chronic concentrated-extract use [2].

Special precautions

Pregnancy

Insufficient human pregnancy safety data; EDA does not recommend medicinal use during pregnancy [6].

Lactation

Milk transfer and infant safety are unknown; EDA does not recommend medicinal use during breastfeeding [6].

Hepatic impairment

No validated hepatic-impairment dosing or safety studies identified in the selected sources; concentrated-extract exposure requires individual clinical assessment [2][6].

Renal impairment

No validated renal-impairment dosing data identified in these sources; potential blood-pressure and diuretic effects warrant individualized assessment with concurrent medicines. This is a precautionary inference, not an impairment-specific clinical finding [2][6].

Sources and references

  1. [1] - McKay DL, Chen CY, Saltzman E, Blumberg JB. Hibiscus sabdariffa L. tea (tisane) lowers blood pressure in prehypertensive and mildly hypertensive adults. The Journal of nutrition, 2010. PMID: 20018807. DOI: 10.3945/jn.109.115097
  2. [2] - Ellis LR, Zulfiqar S, Holmes M, Marshall L, Dye L, Boesch C. A systematic review and meta-analysis of the effects of Hibiscus sabdariffa on blood pressure and cardiometabolic markers. Nutrition reviews, 2022. PMID: 34927694. DOI: 10.1093/nutrit/nuab104
  3. [3] - Frank T, Janssen M, Netzel M, Netzel M, Netzel M, Strass G, Kler A, Kriesl E, Bitsch I. Pharmacokinetics of anthocyanidin-3-glycosides following consumption of Hibiscus sabdariffa L. extract. Journal of clinical pharmacology, 2005. PMID: 15647413. DOI: 10.1177/0091270004270561
  4. [4] - Abubakar SM, Ukeyima MT, Spencer JPE, Lovegrove JA. Acute Effects of Hibiscus Sabdariffa Calyces on Postprandial Blood Pressure, Vascular Function, Blood Lipids, Biomarkers of Insulin Resistance and Inflammation in Humans. Nutrients, 2019. PMID: 30764582. DOI: 10.3390/nu11020341
  5. [5] - Herrera-Arellano A, Flores-Romero S, Chávez-Soto MA, Tortoriello J. Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: a controlled and randomized clinical trial. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2004. PMID: 15330492. DOI: 10.1016/j.phymed.2004.04.001
  6. [6] - Egyptian Drug Authority. Egyptian Herbal Monograph, Hibiscus sabdariffa L. 2025 edition; last revision 26 November 2023. https://www.edaegypt.gov.eg/media/vw3ngdwl/hibiscus-sabdariffa-l-%D9%83%D8%B1%D9%83%D8%AF%D9%8A%D9%87.pdf

Additional source links

Continue browsing